ATE254461T1 - Behandlung von augenschmerzen - Google Patents

Behandlung von augenschmerzen

Info

Publication number
ATE254461T1
ATE254461T1 AT01910734T AT01910734T ATE254461T1 AT E254461 T1 ATE254461 T1 AT E254461T1 AT 01910734 T AT01910734 T AT 01910734T AT 01910734 T AT01910734 T AT 01910734T AT E254461 T1 ATE254461 T1 AT E254461T1
Authority
AT
Austria
Prior art keywords
treatment
eye pain
pain
eye
brimonidine
Prior art date
Application number
AT01910734T
Other languages
English (en)
Inventor
Daniel W Gil
Michael E Stern
John E Donello
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE254461T1 publication Critical patent/ATE254461T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Laser Surgery Devices (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01910734T 2000-02-15 2001-02-15 Behandlung von augenschmerzen ATE254461T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18260900P 2000-02-15 2000-02-15
PCT/US2001/004851 WO2001060347A2 (en) 2000-02-15 2001-02-15 Method for treating ocular pain

Publications (1)

Publication Number Publication Date
ATE254461T1 true ATE254461T1 (de) 2003-12-15

Family

ID=22669224

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01910734T ATE254461T1 (de) 2000-02-15 2001-02-15 Behandlung von augenschmerzen

Country Status (8)

Country Link
US (1) US6294553B1 (de)
EP (1) EP1265601B1 (de)
JP (1) JP4970685B2 (de)
AT (1) ATE254461T1 (de)
AU (2) AU3831301A (de)
CA (1) CA2400377C (de)
DE (1) DE60101265T2 (de)
WO (1) WO2001060347A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20080261893A1 (en) * 2006-02-24 2008-10-23 Denise Barbut Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
AU2008225100A1 (en) * 2007-03-12 2008-09-18 Mayo Foundation For Medical Education And Research Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
US20090004244A1 (en) * 2007-06-27 2009-01-01 Orilla Werhner C Iris design as a drug depot for zonal drug delivery by contact lens
US20090004245A1 (en) * 2007-06-28 2009-01-01 Orilla Werhner C Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
US20100227868A1 (en) * 2007-09-20 2010-09-09 Johnson Brent A Treatment methods with brimonidine
WO2009082452A1 (en) * 2007-12-21 2009-07-02 Dejovin Jack A Pre-surgical treatment
US8198034B2 (en) 2008-03-14 2012-06-12 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20180369240A1 (en) * 2008-08-01 2018-12-27 Eye Therapies Llc Preferential Vasoconstriction Compositions and Methods of Use
US12246013B2 (en) * 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
ES2518418T3 (es) 2008-08-01 2014-11-05 Eye Therapies Llc Composiciones de vasoconstricción y métodos de uso
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
EP2329849B1 (de) 2009-11-18 2015-04-29 Galderma Research & Development Kombination aus einem Alpha-2-Adrenozeptor-Agonisten und einem nichtsteroidalen entzündungshemmenden Mittel zur Behandlung oder Prävention einer Entzündungskrankheit der Haut
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
KR20150058551A (ko) 2010-03-26 2015-05-28 갈데르마 리써어치 앤드 디벨로프먼트 모세혈관 확장증의 안전하고 유효한 치료를 위한 개선된 방법 및 조성물
US8513247B2 (en) 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
WO2011123180A1 (en) 2010-04-03 2011-10-06 Praful Doshi Medical devices including medicaments and methods of making and using same
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
PH12013500738A1 (en) 2010-10-21 2016-08-05 Galderma Sa Brimonidine gel compositions and methods of use
EP2798077A2 (de) 2011-12-31 2014-11-05 Allergan, Inc. Hochempfindlicher zellbasierter test für den nachweis der anwesenheit von aktivem botulinum-neurotoxin-serotyp-a
US10004734B2 (en) * 2016-01-26 2018-06-26 Warren Scherer Compositions and methods for treating rebound erythema associated with topical alpha-adrenergic agonists
EP4555375A1 (de) 2022-07-15 2025-05-21 Praful Doshi Verfahren zur herstellung und verwendung von kontaktlinsen mit arzneimitteln und stabilisatoren labiler komponenten wie etwa arzneimittel

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE129890T1 (de) * 1990-09-07 1995-11-15 Univ Alicante Komposition für die behandlung von augenschmerzen.
JP3683908B2 (ja) * 1993-10-13 2005-08-17 アラーガン、インコーポレイテッド （２−イミダゾリン−２−イルアミノ）キノキサリン誘導体の使用方法
WO2000023066A2 (en) * 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
CA2220517A1 (en) * 1995-05-12 1996-11-14 Allergan Aryl-imidazolines and aryl-imidazoles useful as alpha-2 adrenergic agonists without cardiovascular side effects
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5856329A (en) * 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US5677321A (en) * 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
DK0944601T3 (da) * 1996-11-25 2003-06-10 Procter & Gamble Heterocykliske quanidinylaminoforbindelser som alfa-2-adrenoceptoragonister
BR9813381A (pt) * 1997-12-04 2000-10-03 Allergan Sales Inc "derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c"
US6242442B1 (en) 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions

Also Published As

Publication number Publication date
JP4970685B2 (ja) 2012-07-11
DE60101265D1 (de) 2003-12-24
US20010031754A1 (en) 2001-10-18
DE60101265T2 (de) 2004-08-26
EP1265601A2 (de) 2002-12-18
EP1265601B1 (de) 2003-11-19
AU3831301A (en) 2001-08-27
WO2001060347A2 (en) 2001-08-23
WO2001060347A3 (en) 2002-02-28
AU2001238313B2 (en) 2004-05-27
AU2001238313C1 (en) 2004-11-04
JP2003522785A (ja) 2003-07-29
US6294553B1 (en) 2001-09-25
CA2400377C (en) 2007-11-27
HK1051499A1 (en) 2003-08-08
CA2400377A1 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
DE60101265D1 (de) Behandlung von augenschmerzen
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
DE502004006619D1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE296628T1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
EA200300560A1 (ru) Улучшенный способ лечения
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
DE60218153D1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
ATE383852T1 (de) Kupferchelatbildner zur behandlung von augenentzündungen
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
DE60103685D1 (de) Behandlung von Poriomania
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
ATE422944T1 (de) Superoxiddismutas-mimetika zur behandlung von augenerkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
DE60138385D1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
DE602004024871D1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
DE60017174D1 (de) Rivastigmine zur behandlung von augenerkrankungen
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
LU91009B1 (de) Behandlung von Verbrennungen
DE60330233D1 (de) Arsentherapie zur behandlung von autoimmunerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties